Conditionally replicative adenoviral vectors for malignant glioma.
High-grade gliomas constitute an important challenge to modern medicine, and although great effort has been made to prolong patient survival, the prognosis for this disease remains poor. Due to recent discoveries in the molecular basis of gliomas, gene therapy is becoming a promising alternative. In this review, we discuss the use of conditionally replicative adenoviral vectors (CRAd) and their applications in neuro-oncology. Such vectors, when rendered conditionally replicative via transductional and transcriptional modifications, offer great promise for patients with malignant brain tumours. We review data from preclinical and clinical studies utilising such vectors and discuss the limitations and future perspectives of CRAd oncolytic therapy for malignant glioma.
Sonabend
Adam M
AM
Division of Neurosurgery, The University of Chicago, Chicago, IL 60637, USA.
Ulasov
Ilya V
IV
Lesniak
Maciej S
MS
D000256:Adenoviridae / Q000235:genetics* / Q000502:physiology; D000260:Adenoviruses, Human / Q000235:genetics* / Q000502:physiology; D001932:Brain Neoplasms / Q000235:genetics / Q000628:therapy* / Q000821:virology; D015316:Genetic Therapy / Q000379:methods*; D005822:Genetic Vectors / Q000235:genetics / Q000627:therapeutic use*; D005910:Glioma / Q000628:therapy*; D006801:Humans; D014158:Transcription, Genetic; D014779:Virus Replication